Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children

References

• Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014;28(4):319–329.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Elling C, Tzschentke TM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘µ-load’. Adv Ther. 2018;35(10):1471–1484. doi:10.1007/s12325-018-0778-x
   PubMed Web of Science ®Google Scholar
• Göhler K, Brett M, Smit JW, Rengelshausen J, Terlinden R. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013;51(4):338–348. doi:10.5414/CP201722
   PubMed Web of Science ®Google Scholar
• Smit JW, Oh C, Rengelshausen J, et al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy. 2010;30(1):25–34. doi:10.1592/phco.30.1.25
   PubMed Web of Science ®Google Scholar
• Xiao JP, Li AL, Feng BM, Ye Y, Wang GJ. Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: a systematic review and meta-analysis. Pain Med. 2017;18(1):14–24. doi:10.1093/pm/pnw154
   PubMed Web of Science ®Google Scholar
• Baron R, Eberhart L, Kern KU, et al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract. 2017;17(5):678–700. doi:10.1111/papr.12515
   PubMed Web of Science ®Google Scholar
• Buynak R, Rappaport SA, Rod K, et al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin Ther. 2015;37(11):2420–2438.
   PubMed Web of Science ®Google Scholar
• Finkel JC, Goldberg J, Rosenburg R, et al. First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18. J Pain Res. 2019;12:1925–1936.
   Web of Science ®Google Scholar
• Muse D, Tarau E, Lefeber C, et al. Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients. J Pain Res. 2019;12:1777–1790.
   Web of Science ®Google Scholar
• Beuter C, Volkers G, Radic T, Goldberg J, van den Anker J. Efficacy and safety of multiple doses of tapentadol oral solution in the treatment of moderate to severe acute pain in children aged 2 to <18 years - a randomized, double-blind, placebo-controlled trial. J Pain Res. 2019;12:3099–3112.
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Palexia SR Prolonged Release Tablets. Summary of Product Characteristics. Datapharm PLC; 2020. Available at https://www.medicines.org.uk/emc/product/5158/smpc. Accessed March 20, 2020.
   Google Scholar
• Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain. 2001;93(2):173–183. doi:10.1016/S0304-3959(01)00314-1
   PubMed Web of Science ®Google Scholar
• Guinard JX. Sensory and consumer testing with children. Trends Food Sci Technol. 2001;11(8):273–283. doi:10.1016/S0924-2244(01)00015-2
   Web of Science ®Google Scholar
• Woolery M, Carroll E, Fenn E, et al. A constipation assessment scale for use in pediatric oncology. J Pediatr Oncol Nurs. 2006;23:65–74.
   PubMedGoogle Scholar
• Handelsman L, Cochrane KJ, Aronson M, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293–308. doi:10.3109/00952998709001515
   PubMed Web of Science ®Google Scholar
• Hlavin G, Koenig F, Male C, Posch M, Bauer P. Evidence, eminence and extrapolation. Stat Med. 2016;35(13):2117–2132. doi:10.1002/sim.6865
   Web of Science ®Google Scholar
• Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9(12):1447–1454. doi:10.1002/sim.4780091208
   PubMed Web of Science ®Google Scholar
• Romualdi P, Grilli M, Canonico PL, Collino M, Dickenson AH. Pharmacological rationale for tapentadol therapy: a review of new evidence. J Pain Res. 2019;12:1513–1520. doi:10.2147/JPR.S190160
   PubMed Web of Science ®Google Scholar
• Billeci D, Coluzzi F. Tapentadol extended release for the management of chronic neck pain. J Pain Res. 2017;10:495–505. doi:10.2147/JPR.S129056
   PubMed Web of Science ®Google Scholar
• Kress HG, Coluzzi F. Tapentadol in the management of cancer pain: current evidence and future perspectives. J Pain Res. 2019;12:1553–1560. doi:10.2147/JPR.S191543
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Polati E, Freo U, Grilli M. Tapentadol: an effective option for the treatment of back pain. J Pain Res. 2019;12:1521–1528. doi:10.2147/JPR.S190176
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Pergolizzi JV Jr, Giordan E, Locarini P, Boaro A, Billeci D. Tapentadol prolonged release for managing moderate to severe chronic neck pain with or without a neuropathic component. Curr Med Res Opin. 2020;36(4):651–659. doi:10.1080/03007995.2020.1722083
   PubMed Web of Science ®Google Scholar
• Ballantyne JC. Opioids for the treatment of chronic pain: mistakes made, lessons learned, and future directions. Anesth Analg. 2017;125(5):1769–1778. doi:10.1213/ANE.0000000000002500
   PubMed Web of Science ®Google Scholar
• Krane EJ, Weisman SJ, Walco GA. The national opioid epidemic and the risk of outpatient opioids in children. Pediatrics. 2018;142(2):e20181623. doi:10.1542/peds.2018-1623
   Web of Science ®Google Scholar
• European Medicines Agency. Assessment of the paediatric needs - Pain. 2005. Available from: https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-pain_en.pdf. Accessed February 22, 2020.
   Google Scholar
• Davies EH, Ollivier CM, Saint Raymond A. Paediatric investigation plans for pain: painfully slow! Eur J Clin Pharmacol. 2010;66(11):1091–1097. doi:10.1007/s00228-010-0886-2
   Web of Science ®Google Scholar
• Berde CB, Walco GA, Krane EJ, et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics. 2012;129(2):354–364.
   PubMed Web of Science ®Google Scholar
• Pica N, Bourgeois F. Discontinuation and nonpublication of randomized clinical trials conducted in children. Pediatrics. 2016;138(3):e20160223. doi:10.1542/peds.2016-0223
   PubMed Web of Science ®Google Scholar
• Eccleston C, Fisher E, Cooper TE, et al. Pharmacological interventions for chronic pain in children: an overview of systematic reviews. Pain. 2019;160(8):1698–1707. doi:10.1097/j.pain.0000000000001609
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. CDER Conversation: pediatric pain management options. 2015. Available from: https://www.fda.gov/drugs/news-events-human-drugs/cder-conversation-pediatric-pain-management-options. Accessed May 13, 2020.
   Google Scholar
• Eerdekens M, Beuter C, Lefeber C, van den Anker J. The challenge of developing pain medications for children: therapeutic needs and future perspectives. J Pain Res. 2019;12:1649–1664.
   PubMed Web of Science ®Google Scholar
• King S, Chambers CT, Huguet A, et al. The epidemiology of chronic pain in children and adolescents revisited: a systematic review. Pain. 2011;152(12):2729–2738. doi:10.1016/j.pain.2011.07.016
   PubMed Web of Science ®Google Scholar
• Finkel J, Finley A, Greco C, Weisman S, Zeltzer L. Transdermal fentanyl in the management of children with chronic severe pain: results from an international study. Cancer. 2005;104(12):2847–2857. doi:10.1002/cncr.21497
   Web of Science ®Google Scholar
• US Food and Drug Administration. Pediatric pain and the approach to studying opioid analgesics in pediatric populations. Joint Meeting of the Pediatric Advisory Committee (PAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM); 2019. Available from: https://www.fda.gov/media/131132/download. Accessed February 22, 2020.
   Google Scholar